131I–anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
John M. Pagel(University of Washington), Dana C. Matthews(Fred Hutch Cancer Center), Oliver W. Press(Fred Hutch Cancer Center), Ted Gooley(Fred Hutch Cancer Center), Janet F. Eary(University of Washington), Eneida R. Nemecek(Oregon Health & Science University), Irwin D. Bernstein(Fred Hutch Cancer Center), Katherine Ruffner(Pfizer (United States)), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jeanette Carreras(Medical College of Wisconsin), Paul J. Martin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Darrell R. Fisher(Richland Community College), Mary M. Horowitz(Medical College of Wisconsin), Larry Durack(Fred Hutch Cancer Center), Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Joseph G. Rajendran(Fred Hutch Cancer Center), Eileen Sickle(Fred Hutch Cancer Center)
Cited by 157
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k